26th Nov 2015 09:25
LONDON (Alliance News) - Drug development company Skyepharma PLC on Thursday said trading has been in line with its expectations and said it has made progress on its portfolio.
Skyepharma said trading for the year to the end of December has been in line with its expectations and said its cash position is set to outpace its previous forecasts following a strong performance in the second half.
Its Flutiform asthma treatment has now been approved in 38 countries and launched in 30, with marketing authorisations currently under review in another 15.
Elsewhere, the company said it has started work on its SKP-2075 and SKP-2076 inhaled therapy candidates.
Shares in Skyepharma were up 4.1% to 324.75 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
SKP.L